News Image

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

Provided By GlobeNewswire

Last update: Jan 13, 2025

- Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types

Read more at globenewswire.com

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (2/21/2025, 8:02:48 PM)

After market: 36.85 0 (0%)

36.85

+0.05 (+0.12%)



Find more stocks in the Stock Screener

Follow ChartMill for more